OncoMatch/Clinical Trials/NCT06596915
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Is NCT06596915 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BA1302 for non-small cell lung cancer.
Treatment: BA1302 — This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Breast Carcinoma
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Patients who have progressed on or after standard therapy, or are intolerant of standard therapy, or have no appropriate standard therapy available.
Cannot have received: chemotherapy
Exception: within 28 days prior to the first dose
Received any chemotherapy...within 28 days prior to the first dose.
Cannot have received: radiotherapy
Exception: within 28 days prior to the first dose
Received any...radiotherapy...within 28 days prior to the first dose.
Cannot have received: targeted therapy
Exception: within 28 days prior to the first dose
Received any...targeted therapy...within 28 days prior to the first dose.
Cannot have received: cell therapy
Exception: within 28 days prior to the first dose
Received any...cell therapy...within 28 days prior to the first dose.
Cannot have received: immunotherapy
Exception: within 28 days prior to the first dose
Received any...immunotherapy...within 28 days prior to the first dose.
Cannot have received: antibody-drug conjugate
Exception: within 28 days prior to the first dose
Received any...ADC medication...within 28 days prior to the first dose.
Cannot have received: other anti-cancer treatment
Exception: within 28 days prior to the first dose
Received any...other anti-cancer treatment within 28 days prior to the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06596915 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify